Transition-Metal-Based Nanozymes: Synthesis, Mechanisms of Therapeutic Action, and Applications in Cancer Treatment
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cancer, as one of the leading causes of death worldwide, drives the advancement of cutting-edge technologies for cancer treatment. Transition-metal-based nanozymes emerge as promising therapeutic nanodrugs that provide a reference for cancer therapy. In this review, we present recent breakthrough nanozymes for cancer treatment. First, we comprehensively outline the preparation strategies involved in creating transition-metal-based nanozymes, including hydrothermal method, solvothermal method, chemical reduction method, biomimetic mineralization method, and sol-gel method. Subsequently, we elucidate the catalytic mechanisms (catalase (CAT)-like activities), peroxidase (POD)-like activities), oxidase (OXD)-like activities) and superoxide dismutase (SOD)-like activities) of transition-metal-based nanozymes along with their activity regulation strategies such as morphology control, size manipulation, modulation, composition adjustment and surface modification under environmental stimulation. Furthermore, we elaborate on the diverse applications of transition-metal-based nanozymes in anticancer therapies encompassing radiotherapy (RT), chemodynamic therapy (CDT), photodynamic therapy (PDT), photothermal therapy (PTT), sonodynamic therapy (SDT), immunotherapy, and synergistic therapy. Finally, the challenges faced by transition-metal-based nanozymes are discussed alongside future research directions. The purpose of this review is to offer scientific guidance that will enhance the clinical applications of nanozymes based on transition metals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intrinsic peroxidase-like activity of ferromagnetic nanoparticles
Gao, L., Zhuang, J., Nie, L., Zhang, J., Zhang, Y., Gu, N., Wang, T., Feng, J., Yang, D., Perrett, S., et al. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.260 · Cited by 7,483
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN
Morgan, E., Arnold, M., Gini, A., Lorenzoni, V, Cabasag, C. J., Laversanne, M., Vignat, J., Ferlay, J., Murphy, N., & Bray, F. (2023) · Gut · doi:10.1136/gutjnl-2022-327736 · Cited by 2,429
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379
Tumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449
Stimuli responsive nanosonosensitizers for sonodynamic therapy
Jiang, Z., Xiao, W., & Fu, Q. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.003 · Cited by 173
Self-citationDavies, M. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107685 · Cited by 119
Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA
Schafer, E. J., Jemal, A., Wiese, D., Sung, H., Kratzer, T. B., Islami, F., Dahut, W. L., & Knudsen, K. E. (2023) · European Urology · doi:10.1016/j.eururo.2022.11.023 · Cited by 114
Chai, K., & Xu, S. (2022) · Advanced Powder Technology · doi:10.1016/j.apt.2022.103776 · Cited by 37
A tumor cell exosome-mimicking multifunctional nanozyme for targeted breast cancer radiotherapy
Chen, G., Jiang, D., Ding, S., Huang, C., Zhu, D., & Jiang, H. (2023) · Nanoscale · doi:10.1039/d3nr03065b · Cited by 31
Zhu, L., Dai, Y., Gao, L., & Zhao, Q. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s309062 · Cited by 27
Metadata
- Authors
- Fu, Q., Wei, C., & Wang, M.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-05-02
- Volume
- 18
- Issue
- 19
- Pages
- 12049-12095
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W4396585760
- Cited by
- 196
- References
- 10
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.